David Robinson has over 40 years of commercialization experience in the biopharma industry in multiple therapeutic areas. Mr. Robinson is a proven commercial leader with a history of launching category-defining therapies. He has extensive end-to-end launch expertise spanning strategic launch planning and execution, global market access, reimbursement, building and motivating commercial teams, and spearheading effective sales and marketing programs for groundbreaking therapies in ophthalmology, as well as oncology and HIV.
Mr. Robinson has previously held positions at Merck, Eversana, Regeneron, UCB, Medimmune, and GSK, where he has been a key member of the commercialization leadership team.
Mr. Robinson’s experience at Regeneron Pharmaceuticals, Inc., serves as the foundation of his expertise in ophthalmology. Through his roles as Vice President of Sales and Marketing and Vice President of Sales, Field Access and Reimbursement, he successfully developed and executed the strategic plan to launch Regeneron’s first product to market, EYLEA® (aflibercept). His strategic leadership was pivotal to the successful buildout of highly performing marketing and field teams, ensuring a robust and seamless market entry.
Mr. Robinson received a B.S. in Business Administration from Appalachian State University in Boone, North Carolina.